Mission and Objectives
New drug candidates often have off-target effects resulting in adverse events, thus representing a major limitation for drug R&D. Safety Pharmacology aims to detect, understand and reduce undesirable pharmacodynamic effects early-on. Especially, cardiovascular toxicity is problematic, as it is the most prevalent reason for failure during preclinical development and remains a key reason for drug attrition during clinical development and beyond. The vision of INSPIRE is to advance and “inspire” Safety Pharmacology by exploring new technological capabilities to address emerging cardiovascular safety concerns.
INSPIRE unites expertise from academic teams, technology-providers, pharmaceutical companies, regulators and hospitals to create a European training platform for 15 Early Stage Researchers (ESRs). INSPIRE constitutes a multidisciplinary and intersectoral training programme and will equip the future generation of safety pharmacology scientists with a wide range of scientific knowledge and the ability to adapt to a dynamic industry.
INSPIRE excludes the European Research Executive Agency of responsibility for any communication and any dissemination of results performed by the INSPIRE Team - in compliance with the art. 38.1.3 and 29.5 of the grant agreement 858070.